📊 VYNE Key Takeaways
Is VYNE Therapeutics Inc. (VYNE) a Good Investment?
VYNE demonstrates adequate financial cushion with $24.6M cash and zero debt, but faces critical commercialization failure with near-zero revenue ($86K) despite significant operating losses (-$3.8M) and negative cash flow (-$4.1M). For a pharmaceutical company, minimal revenue suggests failed product launches or stalled pipeline with approximately six years of runway at current burn rate before capital depletion.
VYNE Therapeutics Inc. Key Strengths (VYNE)
- Strong cash position of $24.6M with no long-term debt provides financial runway
- Excellent liquidity metrics (20.86x current ratio) enable debt service and operations
- Positive stockholders' equity of $24.6M maintains solvency and balance sheet integrity
VYNE Stock Risks: VYNE Therapeutics Inc. Investment Risks
- Near-zero revenue ($86K) indicates failed commercialization or stalled product adoption for a pharmaceutical company
- Significant operating losses (-$3.8M) and negative free cash flow (-$4.1M) destroy shareholder value with ROE of -14.6% and ROA of -13.9%
- Finite cash runway of approximately six years at current burn rate without revenue growth creates existential timeline pressure
Key Metrics to Watch
- Revenue growth trajectory and product commercialization progress
- Operating cash flow trend to assess if burn rate is accelerating or stabilizing
- Cash balance depletion rate and remaining runway before capital exhaustion
VYNE Therapeutics Inc. (VYNE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 20.86x current ratio provides a solid financial cushion.
VYNE Profit Margin, ROE & Profitability Analysis
VYNE vs Healthcare Sector: How VYNE Therapeutics Inc. Compares
How VYNE Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is VYNE Therapeutics Inc. Stock Overvalued? VYNE Valuation Analysis 2026
Based on fundamental analysis, VYNE Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
VYNE Therapeutics Inc. Balance Sheet: VYNE Debt, Cash & Liquidity
VYNE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: VYNE Therapeutics Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.93 indicates the company is currently unprofitable.
VYNE Revenue Growth, EPS Growth & YoY Performance
VYNE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $86.0K | -$3.6M | $-0.08 |
| Q2 2025 | $69.0K | -$5.8M | $-0.13 |
| Q1 2025 | $98.0K | -$6.2M | $-0.15 |
| Q3 2024 | $114.0K | -$6.6M | $-0.29 |
| Q2 2024 | $135.0K | -$9.4M | $-0.22 |
| Q1 2024 | $98.0K | -$5.6M | $-0.15 |
| Q3 2023 | $114.0K | -$6.6M | $-2.01 |
| Q2 2023 | $126.0K | -$3.8M | $-1.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VYNE Therapeutics Inc. Dividends, Buybacks & Capital Allocation
VYNE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for VYNE Therapeutics Inc. (CIK: 0001566044)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VYNE
What is the AI rating for VYNE?
VYNE Therapeutics Inc. (VYNE) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VYNE's key strengths?
Claude: Strong cash position of $24.6M with no long-term debt provides financial runway. Excellent liquidity metrics (20.86x current ratio) enable debt service and operations.
What are the risks of investing in VYNE?
Claude: Near-zero revenue ($86K) indicates failed commercialization or stalled product adoption for a pharmaceutical company. Significant operating losses (-$3.8M) and negative free cash flow (-$4.1M) destroy shareholder value with ROE of -14.6% and ROA of -13.9%.
What is VYNE's revenue and growth?
VYNE Therapeutics Inc. reported revenue of $86.0K.
Does VYNE pay dividends?
VYNE Therapeutics Inc. pays dividends, with $16.5M distributed to shareholders in the trailing twelve months.
Where can I find VYNE SEC filings?
Official SEC filings for VYNE Therapeutics Inc. (CIK: 0001566044) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VYNE's EPS?
VYNE Therapeutics Inc. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VYNE's fundamental grade?
Based on our AI fundamental analysis in June 2026, VYNE Therapeutics Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VYNE stock overvalued or undervalued?
Valuation metrics for VYNE: ROE of -14.6% (sector avg: 15%), net margin of -4,168.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VYNE's AI grade for 2026?
Our dual AI analysis gives VYNE Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VYNE's free cash flow?
VYNE Therapeutics Inc.'s operating cash flow is $-4.1M, with capital expenditures of $0.0. FCF margin is -4,745.3%.
How does VYNE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,168.6% (avg: 12%), ROE -14.6% (avg: 15%), current ratio 20.86 (avg: 2).